Citalopram

 

 Buy Article Permissions and Reprints

Citalopram (Cipramil^®, Sepram^® und zahlreiche Generika) ist ein zur chemischen Klasse der bizyklischen Isobenzofuran-Derivate gehörender selektiver Serotonin-Wiederaufnahme-Hemmer (SSRI, Abb. [1]). Es wurde 1996 in Deutschland zur Behandlung depressiver Erkrankungen und Panikstörungen zugelassen.

Abb.1 Struktur von Citalopram.

Literatur

• 1 Keller M B. Citalopram therapy for depression: a review of 10 years of European experience and data from US clinical trials.  J Clin Psychiatry. 2000;  61 896-908
  Google Scholar
• 2 Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro.  J Pharmacol Exp Ther. 1984;  230 94-102
  Google Scholar
• 3 Milne R J, Goa K L. Citalopram: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in depressive illness.  Drugs. 1991;  41 450-477
  Google Scholar
• 4 Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs.  Int Clin Psychopharmacol. 1996;  11 5-11
  Google Scholar
• 5 Melzacka M, Rurak A, Adamus A, Daniel W. Distribution of citalopram in the blood serum and in the central nervous system of rats after single and multiple dosage.  Pol J Pharmacol Pharm. 1984;  36 675-682
  Google Scholar
• 6 Fachinformation: Citalopram (Sepram®); Stand September 2001
• 7 Brosen K, Naranjo C A. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram.  Eur Neuropsychopharmacol. 2001;  11 275-283
  Google Scholar
• 8 Montgomery S A, Pedersen V, Tanghoj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram - a meta-analysis of nine placebo controlled studies.  Int Clin Psychopharmacol. 1994;  9 35-40
  Google Scholar
• 9 Parker N G, Brown C S. Citalopram in the treatment of depression.  Ann Pharmacother. 2000;  34 761-771
  Google Scholar
• 10 Feighner J P, Overo K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.  J Clin Psychiatry. 1999;  60 824-830
  Google Scholar
• 11 Mendels J, Kiev A, Fabre L F. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia.  Depress Anxiety. 1999;  9 54-60
  Google Scholar
• 12 Pollock B G. Citalopram: a comprehensive review Expert.  Opin Pharmacother. 2001;  2 681-698
  Google Scholar
• 13 Patris M, Bouchard J M, Bougerol T, Charbonnier J F, Chevalier J F, Clerc G. et al . Citalopram versus fluoxetine: a double-blind, controlled, multicenter, phase III trial in patients with unipolar major depression treated in general practice.  Int Clin Psychopharmacol. 1996;  11 129-136
  Google Scholar
• 14 Haffmans P MJ, Timmerman L, Hooqduin C A. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicenter study.  Int Clin Psychopharmacol. 1996;  11 157-164
  Google Scholar
• 15 Ekselius L, von Knorring L, Eberhand G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice.  Int Clin Psychopharmacol. 1997;  12 323-331
  Google Scholar
• 16 de Wilde J, Mertens C, Overo K F, Petersen H E. Citalopram versus mianserin: A controlled, double-blind trial in depressed patients.  Acta Psychiatr Scand. 1985;  72 89-96
  Google Scholar
• 17 Ahlfors U G, Elovaura S, Harma P. et al . Clinical multi-centre study of citalopram compared double-blindly with mianserin in depressed patients in Finland.  Nord Psykiatr Tidsskr. 1988;  42 201
  Google Scholar
• 18 Bouchard J M, Delaunay J, Delisle J P, Grasset N, Mermberg P F, Molczadzki M, Pagot R, Richou H, Robert G, Ropert R. et al . Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients.  Acta Psychiatr Scand. 1987;  76 583-592
  Google Scholar
• 19 Rosenberg C, Damsbo N, Fuglum E, Jacobsen L V, Horsgard S. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicenter study.  Int Clin Psychopharmacol. 1994;  9 41-48
  Google Scholar
• 20 Shaw D M, Thomas D R, Briscoe M H, Watkins S E, Crimmins R. A comparison of the antidepressant action of citalopram and amitriptyline.  Br J Psychiatry. 1986;  149 515-517
  Google Scholar
• 21 Gravem A, Amthor K F, Astrup C, Elgen K, Gjessing L R, Gunby B. et al . A double-blind comparison of citalopram (Lu 10 - 171) and amitriptyline in depressed patients.  Acta Psychiatr Scand. 1987;  75 478-486
  Google Scholar
• 22 Danish University Antidepressant Group . Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study.  Psychopharmacology (Berl). 1986;  90 131-138
  Google Scholar
• 23 Baumann P, Nil R, Bertschy G, Jecker A, Brandli H, Morand J, Kasas A, Vuagniaux O, Ramseier F. A double-blind double-dummy study of citalopram comparing infusion versus oral administration.  J Affect Disord. 1998;  49 203-210
  Google Scholar
• 24 Guelfi J D, Strub N, Loft H. Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety andefficacy data from a double-blind, double-dummy trial.  J Affect Disord. 2000;  58 201-209
  Google Scholar
• 25 Montgomery S A, Rasmussen J G, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression.  Int Clin Psychopharmacol. 1993;  8 181-188
  Google Scholar
• 26 Wade A G, Lepola U, Koponen H J, Pedersen V, Pedersen T. The effect of citalopram in panic disorder.  Br J Psychiatry. 1997;  170 549-553
  Google Scholar
• 27 Ostrom M, Eriksson A, Thorson J, Spigset O. Fatal overdose with citalopram.  Lancet. 1996;  348 339-340
  Google Scholar
• 28 Arzneimittel-Telegramm 1996 96: 106-107
• 29 Rasmussen S L, Overo K F, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses.  J Clin Psychopharmacol. 1999;  19 407-415
  Google Scholar
• 30 Meuleman C, Jourdain P, Bellorini M, Sadeg N, Loiret J, Guillard N, Thebault B, Funck F. Citalopram and Torsades de Pointes: A case report.  Arch Mal Coeur Vaiss. 2001;  94 1021-1024
  Google Scholar
• 31 Catalano G, Catalano M C, Epstein M A, Tsambiras P E. QTc interval prolongation associated with citalopram overdose: a case report and literature review.  Clin Neuropharmacol. 2001;  24 158-156
  Google Scholar
• 32 Rothenhausler H B, Hoberl C, Ehrentrout S, Kapfhammer H P, Weber M M. Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker.  Pharmacopsychiatry. 2000;  33 150-152
  Google Scholar
• 33 Barbey J T, Roose S P. SSRI safety in overdose.  J Clin Psychiatry. 1998;  59 42-48
  Google Scholar
• 34 Waugh J, Goa K L. Escitalopram: a review of its use in the management of major depressive and anxiety disorders.  CNS Drugs. 2003;  17 343-362
  Google Scholar
• 35 Lepola U M, Loft H, Reines E H. Escitalopram (10 - 20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.  Int Clin Psychopharmacol. 2003;  18 211-217
  Google Scholar
• 36 Laux G, Dietmaier O, König W. Pharmakopsychiatrie. Urban und Fischer Verlag 2001
  Google Scholar
• 37 Greenblatt D J, von Moltke L L, Harmatz J S, Shader R I. Drug interactions with newer antidepressants: role of human cytochromes P450.  J Clin Psychiatry. 1998;  59 (Suppl 15) 19-27
  Google Scholar
• 38 Dalton S O, Johansen C, Mellemkjaer L, Norgard B, Sorensen H T, Olsen J H. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.  Arch Intern Med. 2003;  163 59-64
  Google Scholar
• 39 de Abajo F J, Rodriguez L A, Montero D S. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.  BMJ. 1999;  319 1106-9
  Google Scholar

Prof. Dr. Thomas Eschenhagen

Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg-Eppendorf

Martinistr. 52

20246 Hamburg